It was demonstrated that these drugs were able to inhibit the synthesis of estrogen that mainly occurs in extragonadal sites (adipose tissue, skin, muscle, bone and central nervous system) in post-menopausal women, and contemporarily affect the enzymatic activity of aromatase in BC cells [17]. This evidence concerns the gene CYP19A1 and breast cancer.